tolvaptan has been researched along with sirolimus in 7 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | tolvaptan (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Edelstein, CL | 1 |
| Hussar, DA | 1 |
| Torres, VE | 1 |
| Steinman, TI | 1 |
| Bellevicine, C; Bisesti, V; Buonocore, P; Cappellaio, F; De Falco, V; Federico, S; Pisani, A; Riccio, E; Russo, L; Sabbatini, M; Troncone, G | 1 |
| Aguiari, G; Bianchi, N; Giattino, A; Giorgi, C; Patergnani, S; Pinton, P | 1 |
3 review(s) available for tolvaptan and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment strategies and clinical trial design in ADPKD.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Benzazepines; Clinical Trials as Topic; Genetic Therapy; Humans; Octreotide; Polycystic Kidney, Autosomal Dominant; Sirolimus; Tolvaptan | 2010 |
Polycystic kidney disease: a 2011 update.
Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtration Rate; Humans; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Indazoles; Kidney; Metformin; Octreotide; Organ Size; Polycystic Kidney, Autosomal Dominant; Sirolimus; Sodium; Tolvaptan | 2012 |
4 other study(ies) available for tolvaptan and sirolimus
| Article | Year |
|---|---|
Therapeutic interventions for autosomal dominant polycystic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Clinical Trials as Topic; Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Octreotide; Polycystic Kidney, Autosomal Dominant; Protein Kinases; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases | 2008 |
New Drugs2010, PART 1.
Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles | 2010 |
Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
Topics: Animals; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Kidney; Male; MAP Kinase Signaling System; Polycystic Kidney Diseases; Rats; Rats, Inbred Strains; Rats, Mutant Strains; Rats, Sprague-Dawley; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Topics: Animals; Apoptosis; Cell Line; Cell Proliferation; Polycystic Kidney, Autosomal Dominant; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases; TRPP Cation Channels | 2023 |